256 related articles for article (PubMed ID: 17169612)
1. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
2. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
4. Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes.
Shirotani K; Tomioka M; Kremmer E; Haass C; Steiner H
Neurobiol Dis; 2007 Jul; 27(1):102-7. PubMed ID: 17560791
[TBL] [Abstract][Full Text] [Related]
5. Regulation of gamma-secretase activity in Alzheimer's disease.
Zhou S; Zhou H; Walian PJ; Jap BK
Biochemistry; 2007 Mar; 46(10):2553-63. PubMed ID: 17298085
[TBL] [Abstract][Full Text] [Related]
6. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
7. The structure and function of Alzheimer's gamma secretase enzyme complex.
Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN
Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215
[TBL] [Abstract][Full Text] [Related]
8. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Kreft AF; Martone R; Porte A
J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
[No Abstract] [Full Text] [Related]
10. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease.
Vardy ER; Catto AJ; Hooper NM
Trends Mol Med; 2005 Oct; 11(10):464-72. PubMed ID: 16153892
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease.
Sheng B; Gong K; Niu Y; Liu L; Yan Y; Lu G; Zhang L; Hu M; Zhao N; Zhang X; Tang P; Gong Y
Free Radic Biol Med; 2009 May; 46(10):1362-75. PubMed ID: 19264123
[TBL] [Abstract][Full Text] [Related]
13. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein.
Laudon H; Winblad B; Näslund J
Physiol Behav; 2007 Sep; 92(1-2):115-20. PubMed ID: 17588625
[TBL] [Abstract][Full Text] [Related]
15. Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
Zetterberg H
Scand J Clin Lab Invest; 2009; 69(1):18-21. PubMed ID: 19199126
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
17. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1.
Boo JH; Sohn JH; Kim JE; Song H; Mook-Jung I
Biochem Biophys Res Commun; 2008 Aug; 372(4):913-7. PubMed ID: 18538664
[TBL] [Abstract][Full Text] [Related]
18. Pore-forming scissors? A first structural glimpse of gamma-secretase.
Steiner H; Than M; Bode W; Haass C
Trends Biochem Sci; 2006 Sep; 31(9):491-3. PubMed ID: 16890442
[TBL] [Abstract][Full Text] [Related]
19. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
20. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
